

Susan Wee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11562894/publications.pdf>

Version: 2024-02-01

18
papers

2,809
citations

623734

14
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

5028
citing authors

#	ARTICLE	IF	CITATIONS
1	PTEN-deficient cancers depend on PIK3CB. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13057-13062.	7.1	490
2	PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers. Cancer Research, 2009, 69, 4286-4293.	0.9	393
3	Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle, 2009, 8, 498-504.	2.6	367
4	BTB/POZ Domain Proteins Are Putative Substrate Adaptors for Cullin 3 Ubiquitin Ligases. Molecular Cell, 2003, 12, 783-790.	9.7	299
5	Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 22299-22304.	7.1	271
6	Fission Yeast COP9/Signalosome Suppresses Cullin Activity through Recruitment of the Deubiquitylating Enzyme Ubp12p. Molecular Cell, 2003, 11, 927-938.	9.7	183
7	The COP9 signalosome: an assembly and maintenance platform for cullin ubiquitin ligases?. Nature Cell Biology, 2003, 5, 1029-1033.	10.3	174
8	CSN facilitates Cullinâ€“RING ubiquitin ligase function by counteracting autocatalytic adapter instability. Nature Cell Biology, 2005, 7, 387-391.	10.3	159
9	PCI proteins eIF3e and eIF3m define distinct translation initiation factor 3 complexes. BMC Biology, 2005, 3, 14.	3.8	126
10	F-Box-Directed CRL Complex Assembly and Regulation by the CSN and CAND1. Molecular Cell, 2009, 35, 586-597.	9.7	110
11	Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of <i>ASCL1</i> Gene Expression. Molecular Cancer Therapeutics, 2015, 14, 2167-2174.	4.1	83
12	Conservation of the COP9/signalosome in budding yeast. BMC Genetics, 2002, 3, 15.	2.7	68
13	Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design. Journal of Medicinal Chemistry, 2021, 64, 14247-14265.	6.4	23
14	Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development. Current Opinion in Oncology, 2008, 20, 77-82.	2.4	21
15	Discovery of Pyridazinone and Pyrazolo[1,5- <i>a</i>]pyridine Inhibitors of C-Terminal Src Kinase. ACS Medicinal Chemistry Letters, 2019, 10, 1486-1491.	2.8	17
16	Abstract 5789: Discovery of clinical candidate BMS-986158, an oral BET inhibitor, for the treatment of cancer. Cancer Research, 2018, 78, 5789-5789.	0.9	13
17	Systemic Loss of C-terminal Src Kinase Expression Elicits Spontaneous Suppurative Inflammation in Conditional Knockout Mice. Veterinary Pathology, 2018, 55, 331-340.	1.7	7
18	DGKÎ¶ exerts greater control than DGKÎ± over CD8 ⁺ T cell activity and tumor inhibition. Oncoimmunology, 2021, 10, 1941566.	4.6	5